Insider Buying: Merus (NASDAQ:MRUS) Major Shareholder Purchases 2,978 Shares of Stock

Merus N.V. (NASDAQ:MRUS) major shareholder A/S Genmab acquired 2,978 shares of the business’s stock in a transaction on Friday, December 26th. The stock was acquired at an average cost of $97.00 per share, for a total transaction of $288,866.00. Following the transaction, the insider directly owned 72,831,487 shares in the company, valued at $7,064,654,239. The trade was a 0.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

A/S Genmab also recently made the following trade(s):

• On Monday, December 29th, A/S Genmab bought 1,052,806 shares of Merus stock. The shares were acquired at an average price of $97.00 per share, with a total value of $102,122,182.00.
• On Friday, December 26th, A/S Genmab bought 142,610 shares of Merus stock. The shares were bought at an average cost of $97.00 per share, with a total value of $13,833,170.00.
• On Wednesday, December 24th, A/S Genmab purchased 96,082 shares of Merus stock. The stock was bought at an average price of $97.00 per share, for a total transaction of $9,319,954.00.
• On Tuesday, December 23rd, A/S Genmab purchased 561,042 shares of Merus stock. The stock was bought at an average cost of $97.00 per share, for a total transaction of $54,421,074.00.
• On Monday, December 22nd, A/S Genmab acquired 15,710 shares of Merus stock. The shares were bought at an average price of $97.00 per share, with a total value of $1,523,870.00.
• On Friday, December 19th, A/S Genmab acquired 66,264 shares of Merus stock. The stock was bought at an average cost of $97.00 per share, with a total value of $6,427,608.00.
• On Thursday, December 18th, A/S Genmab bought 212,177 shares of Merus stock. The stock was bought at an average price of $97.00 per share, for a total transaction of $20,581,169.00.
• On Wednesday, December 17th, A/S Genmab bought 150,795 shares of Merus stock. The shares were bought at an average cost of $97.00 per share, for a total transaction of $14,627,115.00.
• On Tuesday, December 16th, A/S Genmab purchased 120,752 shares of Merus stock. The shares were bought at an average cost of $97.00 per share, with a total value of $11,712,944.00.

Merus Trading Down 7.1%

Shares of NASDAQ MRUS traded down $6.92 during trading hours on Tuesday, reaching $90.00. The stock had a trading volume of 2,728,600 shares, compared to its average volume of 1,265,390. Merus N.V. has a 52-week low of $33.19 and a 52-week high of $97.14. The firm has a market cap of $6.83 billion, a price-to-earnings ratio of -16.98 and a beta of 1.06. The business’s fifty day moving average price is $95.78 and its two-hundred day moving average price is $77.75.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Quarry LP purchased a new stake in Merus during the third quarter valued at approximately $42,000. CWM LLC grew its holdings in Merus by 299.0% in the second quarter. CWM LLC now owns 802 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 601 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in Merus by 10,400.0% in the third quarter. Farther Finance Advisors LLC now owns 525 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 520 shares during the last quarter. Longfellow Investment Management Co. LLC acquired a new position in shares of Merus during the third quarter worth $75,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Merus during the 3rd quarter valued at $114,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

More Merus News

Here are the key news stories impacting Merus this week:

• Positive Sentiment: Major shareholder A/S Genmab executed multiple large purchases of Merus shares across Dec. 16–26 (totaling well over 800,000 shares at ~$97 each), increasing its stake and showing clear insider demand that can be read as confidence in the deal value. SEC Ownership Filing
• Positive Sentiment: Additional filings and reporting highlight several discrete purchases by Genmab (e.g., a 15,710‑share buy disclosed Dec. 22), reinforcing the pattern of insider accumulation ahead of the corporate action. InsiderTrades Article
• Neutral Sentiment: Trading in MRUS was temporarily halted with the stated reason “News pending,” which often precedes material corporate disclosures and contributes to sudden intraday volatility while the market digests the announcement. (Trade‑halt notice from exchange filings/news wires.)
• Neutral Sentiment: Analyst coverage remains mixed-to-neutral (consensus “Hold” and a roughly mid‑$90s target), so broker commentary is unlikely to change the immediate direction absent clarity on deal consideration and timing. MarketBeat MRUS Coverage
• Negative Sentiment: Merus confirmed completion of the transaction with Genmab and that Merus will delist from Nasdaq — a material corporate event that typically ends public trading of the ticker and can trigger forced selling, uncertainty over timing and consideration, and repricing of the remaining float. That delisting/transaction announcement is the most direct reason for the stock’s downward move today. TipRanks: Merus Completes Genmab Acquisition

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Merus in a research note on Wednesday, October 8th. Truist Financial cut shares of Merus from a “buy” rating to a “hold” rating and increased their target price for the stock from $88.00 to $97.00 in a report on Monday, September 29th. Lifesci Capital reissued a “market perform” rating and set a $97.00 target price on shares of Merus in a research report on Tuesday, September 30th. William Blair lowered shares of Merus from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and issued a $97.00 price target on shares of Merus in a research report on Friday, October 31st. Three investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $93.56.

About Merus

Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development.